Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
This week in Healthcare
Healthcare — Aug 10 – Aug 14, 2026 (Wk 33): Healthcare Sector Sees Lift Ahead of Earnings, AI and Emerging Markets in Focus →The healthcare sector experienced a lift this week, particularly in Australia and Hong Kong, as companies prepare for upcoming financial results. Artificial intelligence's impact on investment opportunities and the performance of emerging healthcare markets were also…
A
Deeply overvalued
AGILENT TECHNOLOGIES, INC.
Price$148.45
Model IV$67.71
P/IV1.99
Premium +119%
Return to IV: -54.4%
Market implies +16.0%/yr
vs model +6.5% · above model
AAPG
Valuation N/A
ASCENTAGE PHARMA GROUP INTERNATIONAL
Price$19.00
Model IV—
P/IV—
Limited data — see page
AARD
Valuation N/A
Aardvark Therapeutics, Inc.
Price$7.90
Model IV—
P/IV—
Limited data — see page
ABBV
Fairly valued
AbbVie Inc.
Price$250.33
Model IV$229.05
P/IV1.09
Premium +9%
Return to IV: -8.5%
Market implies +5.0%/yr
vs model +4.5% · in line
ABCL
Valuation N/A
AbCellera Biologics Inc.
Price$6.93
Model IV—
P/IV—
Market implies +98.4%/yr
vs model +2.0% · above model
ABEO
Valuation N/A
ABEONA THERAPEUTICS INC.
Price$5.99
Model IV—
P/IV—
Market implies +53.8%/yr
vs model +18.0% · above model
ABOS
Valuation N/A
Acumen Pharmaceuticals, Inc.
Price$2.44
Model IV—
P/IV—
Limited data — see page
ABT
Fairly valued
ABBOTT LABORATORIES
Price$110.37
Model IV$104.52
P/IV0.82
Premium +6%
Return to IV: -5.3%
Market implies +4.2%/yr
vs model +4.1% · in line
ABUS
Valuation N/A
Arbutus Biopharma Corp
Price$4.63
Model IV—
P/IV—
Market implies +82.6%/yr
vs model +2.0% · above model
ABVC
Valuation N/A
ABVC BIOPHARMA, INC.
Price$0.90
Model IV—
P/IV—
Market implies +60.0%/yr
vs model +2.0% · above model
ABVX
Valuation N/A
Abivax S.A.
Price$130.93
Model IV—
P/IV—
Limited data — see page
ACAD
Deeply overvalued
ACADIA PHARMACEUTICALS INC
Price$29.21
Model IV$10.33
P/IV2.10
Premium +183%
Return to IV: -64.6%
Market implies +28.4%/yr
vs model +18.4% · above model
ACB
Valuation N/A
AURORA CANNABIS INC
Price$3.68
Model IV—
P/IV—
Limited data — see page
ACET
Valuation N/A
Adicet Bio, Inc.
Price$8.38
Model IV—
P/IV—
Limited data — see page
ACHC
Undervalued
Acadia Healthcare Company, Inc.
Price$31.53
Model IV$43.21
P/IV0.54
Discount 27%
Return to IV: +37.0%
Market implies +2.3%/yr
vs model +8.0% · below model
ACHV
Valuation N/A
ACHIEVE LIFE SCIENCES, INC.
Price$6.65
Model IV—
P/IV—
Limited data — see page
ACIU
Valuation N/A
AC Immune SA
Price$2.49
Model IV—
P/IV—
Limited data — see page
ACOG
Valuation N/A
Alpha Cognition Inc.
Price$8.84
Model IV—
P/IV—
Market implies +29.9%/yr
vs model +15.0% · above model
ACON
Valuation N/A
Aclarion, Inc.
Price$2.46
Model IV—
P/IV—
Market implies +31.3%/yr
vs model +5.9% · above model
ACONW
Deeply overvalued
Aclarion, Inc.
Price$0.03
Model IV$0.01
P/IV3.13
Premium +190%
Return to IV: -65.5%
Market implies +12.5%/yr
vs model +2.0% · above model
ACRS
Valuation N/A
Aclaris Therapeutics, Inc.
Price$5.90
Model IV—
P/IV—
Market implies +37.5%/yr
vs model +3.7% · above model
ACRV
Valuation N/A
Acrivon Therapeutics, Inc.
Price$1.95
Model IV—
P/IV—
Limited data — see page
ACTU
Valuation N/A
ACTUATE THERAPEUTICS, INC.
Price$1.01
Model IV—
P/IV—
Limited data — see page
ACXP
Valuation N/A
Acurx Pharmaceuticals, Inc.
Price$1.40
Model IV—
P/IV—
Limited data — see page
ADAG
Valuation N/A
Adagene Inc.
Price$4.11
Model IV—
P/IV—
Market implies +48.0%/yr
vs model +2.0% · above model
ADCT
Valuation N/A
ADC Therapeutics SA
Price$1.01
Model IV—
P/IV—
Market implies +10.5%/yr
vs model +15.0% · below model
ADGM
Valuation N/A
Adagio Medical Holdings, Inc.
Price$0.69
Model IV—
P/IV—
Market implies +45.9%/yr
vs model +15.0% · above model
ADIL
Valuation N/A
ADIAL PHARMACEUTICALS, INC.
Price$3.98
Model IV—
P/IV—
Limited data — see page
ADMA
Deeply undervalued
ADMA BIOLOGICS, INC.
Price$9.47
Model IV$17.37
P/IV0.46
Discount 45%
Return to IV: +83.4%
Market implies -10.6%/yr
vs model +50.0% · below model
ADPT
Valuation N/A
Adaptive Biotechnologies Corp
Price$24.93
Model IV—
P/IV—
Market implies +41.1%/yr
vs model +15.7% · above model
ADTX
Deeply undervalued
Aditxt, Inc.
Price$0.00
Model IV$0.03
P/IV3.91
Discount 93%
Return to IV: +1,400.0%
ADUS
Undervalued
Addus HomeCare Corp
Price$116.06
Model IV$155.68
P/IV0.59
Discount 25%
Return to IV: +34.1%
Market implies +4.9%/yr
vs model +12.3% · below model
ADVB
Valuation N/A
Advanced Biomed Inc.
Price$6.37
Model IV—
P/IV—
Limited data — see page
ADXN
Valuation N/A
Addex Therapeutics Ltd.
Price$5.95
Model IV—
P/IV—
Limited data — see page
AEHR
Valuation N/A
AEHR TEST SYSTEMS
Price$134.06
Model IV—
P/IV—
Market implies +64.6%/yr
vs model +37.3% · above model
AEMD
Valuation N/A
AETHLON MEDICAL INC
Price$2.83
Model IV—
P/IV—
Market implies +23.2%/yr
vs model +15.0% · above model
AEON
Valuation N/A
AEON Biopharma, Inc.
Price$0.28
Model IV—
P/IV—
Limited data — see page
AGEN
Valuation N/A
AGENUS INC
Price$6.96
Model IV—
P/IV—
Market implies +48.1%/yr
vs model +2.0% · above model
AGIO
Valuation N/A
AGIOS PHARMACEUTICALS, INC.
Price$32.27
Model IV—
P/IV—
Market implies +37.4%/yr
vs model +15.0% · above model
AGL
Deeply overvalued
agilon health, inc.
Price$95.51
Model IV$41.18
P/IV2.24
Premium +132%
Return to IV: -56.9%
Market implies +17.7%/yr
vs model +40.5% · below model
AGMB
Valuation N/A
Agomab Therapeutics NV
Price$13.22
Model IV—
P/IV—
Limited data — see page
AHCO
Deeply undervalued
AdaptHealth Corp.
Price$5.81
Model IV$37.20
P/IV0.27
Discount 84%
Return to IV: +540.3%
Market implies -19.1%/yr
vs model +8.1% · below model
AIM
Valuation N/A
AIM ImmunoTech Inc.
Price$0.22
Model IV—
P/IV—
Market implies +13.3%/yr
vs model +2.0% · above model
AIRS
Deeply overvalued
Airsculpt Technologies, Inc.
Price$3.43
Model IV$1.76
P/IV3.06
Premium +95%
Return to IV: -48.8%
Market implies +14.6%/yr
vs model +3.3% · above model
AKAN
Valuation N/A
AKANDA CORP.
Price$6.45
Model IV—
P/IV—
Limited data — see page
AKBA
Deeply overvalued
Akebia Therapeutics, Inc.
Price$0.91
Model IV$0.64
P/IV1.64
Premium +42%
Return to IV: -29.7%
Market implies +3.5%/yr
vs model +2.0% · in line
AKTS
Valuation N/A
Aktis Oncology, Inc.
Price$24.93
Model IV—
P/IV—
Limited data — see page
AKTX
Valuation N/A
Akari Therapeutics Plc
Price$7.54
Model IV—
P/IV—
Limited data — see page
ALC
Deeply undervalued
ALCON INC
Price$74.25
Model IV$213.61
P/IV0.31
Discount 65%
Return to IV: +187.7%
Market implies +2.8%/yr
vs model +21.9% · below model
ALDX
Valuation N/A
Aldeyra Therapeutics, Inc.
Price$1.55
Model IV—
P/IV—
Limited data — see page
ALEC
Valuation N/A
Alector, Inc.
Price$1.78
Model IV—
P/IV—
Market implies +79.1%/yr
vs model +2.0% · above model
ALGN
Deeply overvalued
ALIGN TECHNOLOGY INC
Price$171.16
Model IV$54.97
P/IV3.18
Premium +211%
Return to IV: -67.9%
Market implies +21.1%/yr
vs model +5.7% · above model
ALGS
Valuation N/A
Aligos Therapeutics, Inc.
Price$5.59
Model IV—
P/IV—
Market implies +51.7%/yr
vs model +15.0% · above model
ALKS
Fairly valued
Alkermes plc.
Price$49.17
Model IV$45.18
P/IV0.56
Premium +9%
Return to IV: -8.1%
Market implies +7.0%/yr
vs model +7.1% · in line
ALLO
Valuation N/A
Allogene Therapeutics, Inc.
Price$2.01
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +15.0% · above model
ALLR
Valuation N/A
Allarity Therapeutics, Inc.
Price$1.37
Model IV—
P/IV—
Market implies +66.4%/yr
vs model +15.0% · above model
ALMR
Valuation N/A
Alamar Biosciences, Inc.
Price$33.16
Model IV—
P/IV—
Limited data — see page
ALMS
Valuation N/A
ALUMIS INC.
Price$25.31
Model IV—
P/IV—
Market implies +66.3%/yr
vs model +15.0% · above model
ALNT
Deeply overvalued
ALLIENT INC
Price$111.41
Model IV$33.31
P/IV2.38
Premium +234%
Return to IV: -70.1%
Market implies +24.0%/yr
vs model +8.8% · above model
ALNY
Deeply undervalued
ALNYLAM PHARMACEUTICALS, INC.
Price$219.20
Model IV$347.64
P/IV0.87
Discount 37%
Return to IV: +58.6%
Market implies -11.7%/yr
vs model +44.8% · below model